Haemodynamic Assessment and Outcomes of Aortic Valvuloplasty for Aortic Regurgitation in Patients with Bicuspid Aortic Valve
<b>Background:</b> Aortic valvuloplasty for bicuspid aortic valve carries a risk of postoperative stenosis. We evaluated the haemodynamic differences between aortic valvuloplasty for bicuspid aortic valve, tricuspid aortic valve, and aortic valve replacement by echocardiography. We also assessed whether a higher postoperative pressure gradient affects the outcomes of aortic valvuloplasty for bicuspid aortic valve. <b>Methods:</b> From 2014 to 2021, patients undergoing aortic valvuloplasty were classified into aortic valvuloplasty for bicuspid aortic valve (Group-PB) and aortic valvuloplasty for tricuspid aortic valve (Group-PT). We also enrolled patients undergoing aortic valve replacement (Group-R) between 2002 and 2021. Mid-term outcomes were compared within Group-PB based on peak pressure gradients of ≥20 mmHg (subgroup-H) and <20 mmHg (subgroup-L). <b>Results:</b> Group-PB included 42 patients and Group-PT included 70 patients. Both 7-day and 1-year echocardiography showed the highest peak/mean pressure gradients in Group-PB (<i>n</i> = 41) and the lowest values in Group-PT (<i>n</i> = 67). Propensity scoring analysis yielded similar results to an unadjusted analysis. The mid-term outcomes were not significantly different between subgroup-H (<i>n</i> = 20) and subgroup-L (<i>n</i> = 22), with rates of freedom from aortic regurgitation >II at 5 years of 94.4% vs. 94.4% (<i>p</i> = 0.749) and freedom from reoperation of 94.4% vs. 100.0% (<i>p</i> = 0.317), respectively. <b>Conclusions:</b> Aortic valvuloplasty for tricuspid aortic valve shows favourable valve function in the early postoperative period, whereas aortic valvuloplasty for bicuspid aortic valve has a risk of postoperative stenosis. However, a high pressure gradient (peak pressure gradient of ≥20 mmHg) after aortic valvuloplasty for bicuspid aortic valve does not impact mid-term outcomes.
Authors
- Akihiro Masuzawa (ORCID: https://orcid.org/0000-0002-7018-2597)
- Kenta Murotani (ORCID: https://orcid.org/0000-0003-0623-9365)
- Satoshi Arimura (ORCID: https://orcid.org/0000-0002-7659-5632)
- Kosuke Saku (ORCID: https://orcid.org/0000-0002-2940-5728)
- Takashi Kunihara (ORCID: https://orcid.org/0000-0001-6903-6501)
- Yoko Matsumura (ORCID: https://orcid.org/0000-0002-3438-2161)
- Ryuichi Nagahori
- Michio Yoshitake
- Tomomitsu Takagi
Institutions
- Kurume University (JP)
- Jikei University School of Medicine (JP)
- Cardiovascular Institute Hospital (JP)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2024-12-11
- DOI
- https://doi.org/10.3390/jcm13247544
- Citations
- 1
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- Jikei University School of Medicine